# US 2024/0307469 A1 · Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0307469 A1
- Document ID: US20240307469A1
- Status: Published application
- Kind: A1
- Application number: 18/680,187
- Filed: 2024-05-31
- Published: 2024-09-19
- Earliest claimed: 2017-11-24
- Assignees: Ottawa Hospital Research Institute
- Applicants: Ottawa Hospital Research Institute
- Inventors: Jean-Simon Diallo; Mohammed Selman; Rozanne Arulanandam; Nicole Elise Forbes; Ramya Krishnan
- Web page: https://patentgrep.com/patent/US20240307469A1

## CPC

- A61K 35/766: Rhabdovirus, e.g. vesicular stomatitis virus
- A61K 31/225: Polycarboxylic acids
- A61P 35/00: Antineoplastic agents
- C07C 69/60: Maleic acid esters; Fumaric acid esters
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/585: {wherein the target is cancer}
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10351: Methods of production or purification of viral material
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/20232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/20251: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are fumaric-containing compounds, compositions comprising the same and methods for using such compounds for increasing the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues. Also provided are methods for increasing the capacity of an interferon-sensitive virus to produce a virus-encoded transgene from a cell, by administering the compounds and compositions.

## Claims

### Claim 1

A method for increasing the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues, the method comprising:
administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,
wherein R1 and R2 are each independently OH, (C1-2)alkoxy or linear, branched or cyclic, saturated or unsaturated (C3-20)alkoxy; said alkoxy is optionally substituted with one or more halogen, OH, (C1-4) alkyl, nitro or cyano;
wherein when one of R1 and R2 is OH, the other of R1 and R2 is not OH,
to the cell before, concurrently with, or after infection of the cell with the interferon-sensitive virus.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus is a non-interferon-sensitive virus genetically rendered interferon-sensitive, an attenuated interferon-sensitive virus, an interferon-sensitive oncolytic virus, or a non-replicating interferon-sensitive virus.

### Claim 3 (depends on 1)

The method according to claim 1, wherein death of the infected cell or neighboring uninfected cells is enhanced, increased or potentiated directly from a virally encoded component or indirectly through an immune response or an increase in the yield of virus produced from the cell.

### Claim 4 (depends on 1)

The method according to claim 1, wherein an immunotherapeutic activity of the interferon-sensitive virus in the cell or tissues is enhanced, increased or potentiated.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the compound of Formula (I) is or comprises the structure of: Dimethylfumarate (DMF), diethylfumarate (DEF), monoethyl fumarate, or monomethyl fumarate (MMF), or a pharmaceutically acceptable salt or solvate thereof.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus is a reovirus, newcastle disease virus, polio virus, mumps virus, measles virus, influenza virus, Maraba virus MG-1, Rabies virus, Rotavirus, Hepatitis A virus, Rubella virus, Dengue virus, Chikungunya virus, Respiratory Syncytial Virus, LCMV, lentivirus, replicating retrovirus, adenovirus, adeno-associated virus, herpes simplex virus or rhabdovirus, or a variant or derivative thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus comprises a rhabdovirus which is vesicular stomatitis virus or a derivative or variant thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus comprises a virus selected under specific growth conditions, subjected to one or more selection pressures, genetically modified using a recombinant technique, or any combination thereof.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the cell is mammalian.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the cell is human.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the one or more tissues are selected from bone, breast, skin, kidney, lung, ovary, muscle, colon, and prostate.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus is a virus used to prepare a vaccine, wherein the virus is a component of the vaccine, or the vaccine comprises the cell infected with the virus.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus is a virus used as a gene therapy vector.

### Claim 14 (depends on 1)

The method according to claim 1, wherein an immunotherapeutic activity of the interferon- sensitive virus in the cell or tissues is enhanced, increased or potentiated for up-regulation of virus encoded transgenes and/or cytokines.

### Claim 15 (depends on 1)

The method of claim 1, wherein the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues is increased as compared to the capacity of an interferon-sensitive virus to infect, transduce, grow or replicate in a cell or spread within one or more tissues in the absence of the compound of Formula (I) or pharmaceutically acceptable salt or solvate thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is a compound represented by Formula (III) or a pharmaceutically acceptable salt or solvate thereof,
wherein Ra and Rb are the same or different and are each independently selected from hydrogen and C1-10 alkyl, optionally substituted with one or more halogen, OH, (C1-4) alkyl, nitro or cyan, and at least one Ra or Rb is C1-10 alkyl, optionally substituted with one or more halogen, OH, (C1-4) alkyl, nitro or cyano.

### Claim 17

A method for increasing the capacity of an interferon-sensitive virus to produce a virus-encoded transgene from a cell, which comprises administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof,
wherein R1 and R2 are each independently OH, (C1-2)alkoxy or linear, branched or cyclic, saturated or unsaturated (C3-20)alkoxy; said alkoxy is optionally substituted with one or more halogen, OH, (C1-4) alkyl, nitro or cyano;
wherein when one of R1 and R2 is OH, the other of R1 and R2 is not OH,
to a subject before, after, or concurrently with administering the interferon-sensitive virus to the subject.

### Claim 18 (depends on 1)

The method of claim 1, wherein the compound is administered in vivo or ex vivo.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the interferon-sensitive virus is used to prepare a therapeutic, wherein the therapeutic comprises the cell infected with the interferon-sensitive virus.

### Claim 20 (depends on 1)

The method according to claim 1, wherein a therapeutic activity of the interferon-sensitive virus in the cell or tissues is enhanced, increased or potentiated for up-regulation of virus encoded transgenes and/or cytokines.
